New data includes a study in over 5,000
patients—the largest intragastric balloon weight loss study ever
conducted
Allurion (NYSE: ALUR), a company dedicated to ending obesity,
today announced the acceptance of nine scientific presentations at
the upcoming 26th World Congress of the International Federation
for the Surgery of Obesity and Metabolic Disorders (IFSO). These
presentations consist of four abstracts that will be presented as
oral presentations, four abstracts that will be presented as
posters, and one moderated presentation. IFSO takes place in
Naples, Italy, from August 30 to September 1.
Presentations will include data from a global study in over
5,000 patients treated with the Allurion Program, data on combining
weight-loss drugs with the Allurion Program, and data on the impact
of the Allurion Program on diabetes.
"We are pleased to have the opportunity to present this data at
such a prestigious forum. I believe these abstracts will further
demonstrate that the Allurion Program can offer a scalable weight
loss solution that can be combined with newer weight loss drugs and
also have a significant impact on co-morbidities like diabetes,”
said Dr. Shantanu Gaur, Founder and CEO of Allurion.
Details of the oral presentations are as follows:
Title: Effectiveness of Semaglutide for the Management of
Weight following Sleeve Gastrectomy and Intra Gastric Balloon
Therapy Presenter: Mohammad Jamal, M.D., Kuwait University
Presentation Date: Wednesday, August 30th, 13:12-13:19
Title: Resolution of Diabetes with Swallowable Balloon
Therapy Presenter: Mohit Bhandari, M.D., Founder and
Director, Mohak Bariatrics and Robotics Presentation Date:
Wednesday, August 30th, 15:35-15:42
Title: The Swallowable Gastric Balloon: Global Experience
in 5003 Consecutive Patients – The Largest Gastric Balloon Study in
the World Presenter: Roberta Ienca, M.D., Weight Management
Center, Nuova Villa Claudia Clinic Presentation Date:
Wednesday, August 30th, 15:49-15:56
Title: Swallowable Intragastric Balloons: First
Argentinian Experience Presenter: Mariano Palermo, M.D.,
Director of Bariatric Surgery, Centro CIEN – DIAGNOMED
Presentation Date: Wednesday, August 30th, 15:56-16:03
Title: The swallowable balloon – professional treatment
of obesity or preventive life-style intervention that anyone can
apply? Presenter: Mohit Bhandari, M.D., Founder and
Director, Mohak Bariatrics and Robotics Presentation Date:
Thursday, August 31st, 09:10-09:20
Details of the poster presentations are as follows:
Title: Can endoscopic procedures like balloons and
endoscopic sleeve gastroplasty help in increasing bariatric surgery
practice? Presenter: Mohit Bhandari, M.D., Founder and
Director, Mohak Bariatrics and Robotics Poster: P-56
Title: Combination therapy of GLP-1 analogues with
Swallowable Balloon for treatment of obesity Presenter:
Winni Mathur, Mohak Bariatrics and Robotics Poster: P-68
Title: Integrated approach for patients with overweight
and obesity treated with swallowable intragastric balloon
Presenter: Salvatore Avallone, M.D., Clinique Cap D’Or
Poster: P-197
Title: Outcomes of a Swallowable Intragastric Balloon on
96 Overweight and Obese Patients Presenter: Mahmoud
Abdelaal, M.D., Assiut University Hospital Poster: P-273
For more information about IFSO, please visit:
https://www.ifso2023.org/.
About Allurion
Allurion is dedicated to ending obesity. The Allurion Program is
a weight-loss platform that combines the Allurion Gastric Balloon,
the world’s first and only swallowable, procedure-less gastric
balloon for weight loss, the Allurion Virtual Care Suite, including
the Allurion Mobile App for consumers, Allurion Insights for
healthcare providers featuring the Iris AI Platform, and the
Allurion Connected Scale and Health Tracker devices. The Allurion
Virtual Care Suite is also available to providers separately from
the Allurion Program to help customize, monitor and manage
weight-loss therapy for patients regardless of their treatment
plan: gastric balloon, surgical, medical or nutritional. The
Allurion Gastric Balloon is an investigational device in the United
States.
For more information about Allurion and the Allurion Virtual
Care Suite, please visit www.allurion.com.
Forward-Looking Statements
This press release may contain certain forward-looking
statements within the meaning of the federal securities laws. These
forward-looking statements generally are identified by the words
“believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,”
“strategy,” “future,” “opportunity,” “plan,” “may,” “should,”
“will,” “would,” “will be,” “will continue,” “will likely result,”
and similar expressions and include statements regarding Allurion’s
expectations for, and market acceptance of, the Allurion Program.
They reflect the current beliefs and assumptions of Allurion’s
management based on information currently available to them.
Forward-looking statements are predictions, projections and other
statements about future events that are based on current
expectations and assumptions and, as a result, are subject to risks
and uncertainties. Many factors could cause actual future results
or developments to differ materially from the forward-looking
statements in this communication, including but not limited to (i)
the ability of Allurion to obtain regulatory approval for and
successfully commercialize the Allurion Program, (ii) the results
of clinical data from its studies, (iii) the evolution of the
markets in which Allurion competes, (iv) the ability of Allurion to
defend its intellectual property and satisfy regulatory
requirements, (v) the impact of the COVID-19 pandemic on Allurion’s
business, (vi) Allurion’s expectations regarding its market
opportunities and (vii) the risk of downturns and a changing
regulatory landscape in the highly competitive industry in which
Allurion operates. The foregoing list of factors is not exhaustive.
You should carefully consider the foregoing factors and the other
risks and uncertainties described in the “Risk Factors” section of
the proxy statement/prospectus contained in Allurion’s Registration
Statement on Form S-4 (333-271862), the company’s Form 8-K filed on
August 7, 2023 (as amended), and other documents filed by Allurion
from time to time with the U.S. Securities and Exchange Commission.
These filings identify and address other important risks and
uncertainties that could cause actual events and results to differ
materially from those contained in the forward-looking statements.
Forward-looking statements speak only as of the date they are made.
Readers are cautioned not to put undue reliance on forward-looking
statements, and Allurion assumes no obligation and does not intend
to update or revise these forward-looking statements, whether as a
result of new information, future events, or otherwise. Allurion
does not give any assurance that it will achieve its
expectations.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230828916380/en/
Media Contacts Global Cedric Damour PR Manager +33
7 84 21 02 20 cdamour@allurion.com
USA Erik Milster SeriesM PR 508.740.6125
emilster@seriesmpr.com
Allurion Technologies (NYSE:ALUR)
過去 株価チャート
から 4 2024 まで 5 2024
Allurion Technologies (NYSE:ALUR)
過去 株価チャート
から 5 2023 まで 5 2024
